Domestic launch date of Sotoracib (AMG510)

Sotoracib (AMG510) is a targeted drug for KRAS G12C mutant tumors. Although it has been marketed abroad and approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), it has not yet been marketed domestically. It is currently understood that the drug may have been approved for clinical trials in China, but the specific launch time has not yet been determined and needs to wait for approval from the National Medical Products Administration. The overseas R&D and manufacturer of sotoraxib is the American company Amgen. It is a small molecule inhibitor that inhibits the activity of KRAS G12C mutant protein by binding to it, thereby blocking the growth and spread of tumor cells.